Celltrion proves equivalent effect on Remsima, Remicade and Humira
At the 2018 European Crohn’s and Colitis Organisastion(ECCO) held in Vienna, Austria, large clinical study results on Crohn’s disease patients were revealed.
In these studies, the remission rate of each patient group with Remsima, Remicade and Humira was 39.0%, 39.7% and 32.7% respectively, show...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
